A small proteoglycan that contains only a single dermatan sulfate chain is the main proteoglycan synthesized by skin fibroblasts. Fibroblasts from a patient with progeroidal appearance and symptoms of the Ehlers-Danlos syndrome have a reduced ability of converting the core protein of this proteoglycan into a mature glycosaminoglycan chainbearing species. This abnormality is the consequence of a deficiency in galactosyltransferase I (xylosylprotein 4-,B-galactosyltransferase; EC 2.4.1.133), which catalyzes the second glycosyl transfer reaction in the assembly of the dermatan sulfate chain. The glycosaminoglycan-free core protein secreted by the patient's fibroblasts bears an unsubstituted xylose residue. The mutant enzyme is abnormally thermolabile. Preincubation of fibroblasts at 41°C leads to a further reduction in the production of mature proteoglycan and affects the capacity for glycosaminoglycan synthesis on p-nitrophenyl f8-D-xyloside more strongly in the mutant than in control cells.
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The occurrence of inborn errors in the metabolism of connective tissue proteoglycans in humans has long been recognized, and over the past two decades the basic genetic defects in many of these disorders have been elucidated. The majority of the diseases are caused by faulty degradation of the polysaccharide components ofthe proteoglycans (see ref. 1 for a review). In a few instances, defects in the biosynthesis of proteoglycans have been demonstrated in experimental animals, such as impaired posttranslational processing of the cartilage proteoglycan core protein in nanomelic chicken (2) and a tissue-specific deficiency in the biosynthesis of 3'-phosphoadenylylsulfate in brachymorphic mice (3) . Defective biosynthesis of proteoglycans is probably the cause of the connective tissue abnormalities observed in several diseases in humans, including macular corneal dystrophy (4) and a form of spondyloepiphyseal dysplasia (5), though the defects in these diseases have not yet been elucidated.
We have previously described a patient who represented a progeroid variant with signs of the Ehlers-Danlos syndrome (6) . In addition to aged appearance, developmental delay, dwarfism, craniofacial dysproportion, and generalized osteopenia, this patient suffered from defective wound healing, hypermobile joints, hypotonic muscles, and loose but elastic skin. Biochemically, his cultured skin fibroblasts were defective in the biosynthesis of a ubiquitous proteoglycan named small dermatan sulfate proteoglycan II (DS-PG II; refs. 7 and 8) or decorin (9) , which consists of an Mr 36,319 core protein (10), a single glycosaminoglycan chain on the serine residue at position 4 (11) , and either two or three asparagine-bound oligosaccharides (12) . The fibroblasts synthesized normal amounts of this core protein but converted at most 80% and in some experiments as little as 20% into mature proteoglycan molecules. The remainder was secreted in a glycosaminoglycan-free form.
We had discussed previously that the patient could carry a mutant allele yielding a core protein with an absent or buried recognition site for the attachment of the glycosaminoglycan chain. In light of the limited induction of glycosaminoglycan biosynthesis in the presence of low concentrations of pnitrophenyl ,B-D-xyloside, which serves as an artificial stimulator ofglycosaminoglycan synthesis, an abnormality in one of the enzymes involved in the synthesis of the polysaccharideprotein linkage region, GlcA(J31-3)Gal(J31-3)Gal(J31-4)Xyl, was also considered. The results presented in this paper provide evidence that the second explanation is the correct one. (14) . UDP [4,5- (14) . Briefly, proteins were Abbreviation: DS-PG I1, small dermatan sulfate proteoglycan II.
1342
The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. precipitated with ethanol, and the soluble material was subjected to cation-exchange chromatography for the purification of the radioactive product. Without exception, the purity of the radioactive products, Gal-Xyl-Ser or Gal-Gal-Xyl-Ser, was subsequently checked by high-voltage electrophoresis (14) and determination of the 3H radioactivity in 1-cm paper segments. By-products accounted for up to 10% in the control cell lines and 50o in the patient's fibroblasts, and the ion-exchange data were corrected correspondingly.
Preparation of DS-PG II and Its Core Protein. Conditioned medium that contained only insulin and transferrin as exogenously supplied proteins (18) served as the source of unlabeled DS-PG II and core protein. Glycosaminoglycan-free core protein and DS-PG II were separated from each other by anion-exchange chromatography (12) . Core protein-containing fractions were dialyzed against 0.1% Triton X-100, lyophilized, and immune precipitated with an affinitypurified antiserum against DS-PG II core protein (12) . DS-PG II-containing fractions were similarly dialyzed and Iyophilized but were then exhaustively digested with chondroitin ABC Iyase (19) . Both preparations were subjected to preparative SDS/polyacrylamide gel electrophoresis (20) . Proteins were visualized by treating the gels with 1 M KCI (21) , and bands ofinterest were electroeluted. After drying the samples under reduced pressure, salts were removed by washing with methanol. The secretion of [3H]leucine-labeled DS-PG II and core protein was followed as described (12) .
Identification of Xylose Residues. Core protein and chondroitin ABC Iyase-digested DS-PG II from 240 ml of conditioned medium were dissolved in 20 ILI of 0.92 M Na3HB4 (specific activity, 929 GBq/mol) in 0.1 M NaOH and incubated for 21 hr at 50'C. After acidification to pH 5 with acetic acid, each sample was concentrated to dryness, and the residue was evaporated three times with methanol. The samples were then subjected to descending paper chromatography for 14 hr on Schleicher & Schuell paper no. 2043 BMGL in butanol/acetone/H20, 2:7:1. Samples that had been hydrolyzed under nitrogen with 1 M HCl for 4 hr at 105'C were analyzed in parallel. The radioactive peak migrating as authentic [3H]xylitol was eluted with H20 and applied either to a carbohydrate analysis column or to an Aminex HPX-87 H column. The first column was eluted at ambient temperature with 80% acetonitrile in H20 at a flow rate of 1 ml/min; the second column was operated at 40°C and was eluted with 3 mM H2SO4 in 15% acetonitrile in H20 at a flow rate of 0.5 ml/min.
Other Methods. The secretion ofglycosaminoglycan chains induced on exogenously added p-nitrophenyl /3-D-xyloside was measured as described (6) . Briefly, fibroblasts were (Fig. 2) . The low activity of the mutant enzyme made it necessary, however, to choose 1 hr as the standard incubation period.
Surprisingly, the patient's fibroblasts were also deficient in galactosyltransferase II, the activity being only 20% of the mean normal value. Activities below the range of 1 standard deviation were found in the cells from his parents (Table 1) .
Galactosyltransferase I activity was also determined by using p-nitrophenyl 83-D-xyloside (5 mM) as substrate under otherwise identical conditions. The radioactive product was quantitated by chromatography on a 1 x 7 cm Bio-Gel P2 column in H20 where its elution volume was 1.75 times that of 3H20. Two control cell strains exhibited activities of 480 and 600 fmol/min per mg of protein, respectively, whereas in the patient's cells the activity was below the limit of detection (<50 fmol/min per mg).
Properties In a fibroblast homogenate, galactosyltransferase I did not function optimally at 370C. Instead, the normal enzyme exhibited the highest activity at 30°C, and the mutant enzyme was most active at 250C, the lowest temperature tested (Fig.  3 ). There were no differences in the temperature optima of galactosyltransferase II, which were at 300C in both cases.
The effect of temperature on glycosaminoglycan chain formation in intact cells is illustrated in Fig. 4 contrast, mature proteoglycan molecules were the major products after preincubation at 370C and 300C, and free core protein accounted for only 18% and 13%, respectively, of the total radioactivity in the immunoreactive material. Furthermore, it should be noted that the total incorporation of [3H]leucine, in control as well as patient cells, was reduced by about 60% when the preincubation was carried out at 410C rather than at 300C or 370C. In addition to the temperature sensitivity, Fig. 4 (6) . Examination of the effect of temperature on the induction of glycosaminoglycan chain formation (Table 2) showed that mutant and control cells had a reduced ability to synthesize free chains after preincubation at 41°C rather than 37°C. However, the patient's fibroblasts were about twice as sensitive as normal cells. DISCUSSION This investigation has shown that cultured fibroblasts from a patient with a progeria-like syndrome and signs ofthe EhlersDanlos syndrome are severely deficient in galactosyltransferase I, which catalyzes the second glycosyl transfer step in the biosynthesis of several connective tissue polysaccharides. Additional findings indicate that this deficiency is the primary genetic defect in this syndrome and that it is inherited in an autosomal recessive manner. Thus, the patient's enzyme was more thermolabile than its normal counterpart, a property often observed in mutant enzymes. Furthermore, both parents exhibited only half of the mean normal enzyme activity in their fibroblasts.
Consonant with the profound enzyme deficiency was the accumulation in the culture medium of incomplete proteoglycan molecules without a glycosaminoglycan chain but possessing an unsubstituted xylose residue attached to the core protein of DS-PG II. However, mature proteoglycan molecules with glycosaminoglycan chains ofincreased length were also present and represented, in several experiments, the majority of the material reacting with an antibody to the DS-PG II core protein. Although we do not know what fraction of the normal galactosyltransferase I activity is sufficient to sustain a normal level of proteoglycan biosynthesis in vivo, it seems likely that the profound deficiency observed in vitro should have reduced substantially the capacity of intact fibroblasts to synthesize mature DS-PG II. A possible explanation of the fact that this did not occur is that the physiological acceptor-the xylosylated core protein-may be a much better substrate than the two artificial substrates used in this study. Attempts were therefore made to use the core protein secreted by the patient's fibroblasts as a galactose acceptor for partially purified galactosyltransferase I. Although galactose was indeed incorporated, characterization of the product indicated that the sugar had been transferred only to asparagine-bound oligosaccharides (E.Q., unpublished work).
A second explanation of the high level of proteoglycan synthesis in the intact cells is that the mutant enzyme may be more stable in its native environment than in the cell-free extract. Galactosyltransferase I in normal cells is firmly bound to intracellular membranes, and disruption of the membrane structure-e.g., by digestion with phospholipase C-results in partial inactivation (22) . Whereas solubilized, purified preparations of the normal enzyme are fairly stable in the presence of appropriate phospholipids or nonionic detergents, the mutant enzyme may be more sensitive to perturbations of its native environment and may have lost activity during preparation of the cell-free extract.
The possibility should also be considered that a "nonspecific" galactosyltransferase may augment the activity of galactosyltransferase I in the mutant cells in vivo. Lactose synthase is known to catalyze galactose transfer to xylose, albeit with low efficiency. However, the increased thermal sensitivity of the patient's fibroblasts with respect to formation of DS-PG II argued against the involvement of a nonspecific normal galactosyltransferase. The same conclusion emerges from the results of experiments with the artificial substrate, p-nitrophenyl 8-D-xyloside. Again illustrating the discrepancy between the results of in vitro and in vivo studies, the experiments showed no measurable galactosyltransferase I activity in extracts of the patient's cells at a xyloside concentration of 5 mM, but a marked stimulation of glycosaminoglycan synthesis occurred in vivo in the presence of 1 mM xyloside. At elevated culture temperature, the decrease in glycosaminoglycan chain formation was substantially greater in the mutant cells than in normal cells, supporting the view that the mutant enzyme and not a nonspecific galactosyltransferase was the target of the thermal effect.
Interestingly, a deficiency in galactosyltransferase II, which catalyzes the third glycosyl transfer step in polysaccharide chain assembly, was also observed. Although an explanation of this finding is not yet apparent, the possibility may be suggested that the two galactosyltransferases share a common subunit, which is the target ofthe mutation. It is also possible that galactosyltransferase II participates in the formation of a multienzyme complex containing all glycosyltransferases required for synthesis of the glycosaminoglycanprotein linkage region and that the instability of galactosyltransferase I may render other components of the complex more labile. The known ability of galactosyltransferase I to form complexes with xylosyltransferase in vitro (23, 24) is consistent with this notion. On the other hand, no deficiency in xylosyltransferase was observed in the patient's cells, and the finding that xylosyltransferase and galactosyltransferase I are not coordinately synthesized and degraded (22) leaves doubts as to the physiological importance of the complex formation observed in vitro.
The different chondroitin sulfate/dermatan sulfate and heparan sulfate proteoglycans contain the same glycosaminoglycan-protein linkage region (13) . Studies with Chinese hamster ovary cell mutants suggested that a single xylosyltransferase (16) and a single galactosyltransferase I (25) are involved in the biosynthesis of these proteoglycans. It is not known whether human fibroblasts express one or several proteins with galactosyltransferase I activity. If human fibroblasts behave like Chinese hamster ovary cells, defects in the biosynthesis of the large dermatan sulfate proteoglycan and of heparan sulfate proteoglycans would be expected in the patient. However, normal urinary excretion of heparan sulfate and normal [35S]sulfate incorporation into fibroblast proteoglycans other than DS-PG II have been observed previously (6) . In light of the fact that the mature DS-PG II from the patient contains abnormally long dermatan sulfate chains, P'S]sulfate incorporation studies do not exclude the possibility that the core proteins of the large dermatan sulfate proteoglycan and/or of heparan sulfate proteoglycans are substituted with a reduced number of glycosaminoglycan chains. Further studies are required to exclude with certainty a defect in the biosynthesis of these proteoglycans.
In spite of the many unanswered questions outlined above, it appears certain that we have observed a human defect in the biosynthesis of the carbohydrate backbone of a connective tissue polysaccharide, and the diploid human-cell line carrying the defect should be a valuable tool in future studies of various cell/matrix interactions.
